FluoGuide A/S AI Stock Analysis
Want to see SE:FLUO full AI Analyst Report?
FluoGuide A/S (FLUO) AI Stock Analysis
FluoGuide A/S
(Nasdaq OMX AB:FLUO)
The score is held down primarily by very weak financial performance—minimal revenue, large ongoing losses, and heavy cash burn—along with rising leverage. Technicals add further pressure as the stock trades below major moving averages with negative MACD. Valuation provides limited support because the company is loss-making (negative P/E) and there is no dividend yield data.
FluoGuide A/S (FLUO) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 472.49M
- Dividend Yield
- ―
- Average Volume (3M)
- 4,925
- Price to Earnings (P/E)
- -6.5
- Beta (1Y)
- 0.16
- Revenue Growth
- ―
- EPS Growth
- -23.57%
- Country
- Sweden
- Employees
- 7
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
FluoGuide A/S Business Overview & Revenue Model
Company Description
FluoGuide A/S is a Danish life science company dedicated to developing and commercializing advanced surgical solutions. Its flagship investigational compound, FG001, is currently undergoing Phase I/II clinical trials for the treatment of high-grade g...
How the Company Makes Money
FluoGuide’s business model is centered on developing proprietary fluorescence imaging agents and monetizing them through (1) future commercial sales (if/when regulatory approvals are obtained) and/or (2) partnering and licensing transactions with lar...
FluoGuide A/S Financial Statement Overview
Summary
Overall financial quality is weak: revenue is minimal and declining, losses are very large with deeply negative margins, and operating/free cash flow show heavy ongoing cash burn. The balance sheet still has positive equity, but leverage has risen to near parity with equity, reducing flexibility if losses persist.
Income Statement
9Very NegativeBalance Sheet
38NegativeCash Flow
14Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 54.00K | 0 | 385.00K | 423.00K | 6.51M | 9.61M |
| Gross Profit | -416.92K | -571.17K | 385.00K | 423.00K | 6.51M | 9.61M |
| EBITDA | -48.08M | -40.42M | -32.58M | -43.66M | -32.21M | -28.65M |
| Net Income | -46.24M | -40.39M | -28.96M | -38.38M | -27.34M | -23.77M |
Balance Sheet | ||||||
| Total Assets | 65.25M | 88.34M | 28.38M | 29.61M | 35.62M | 53.31M |
| Cash, Cash Equivalents and Short-Term Investments | 49.92M | 78.84M | 18.61M | 21.67M | 26.01M | 46.76M |
| Total Debt | 27.56M | 28.30M | 624.00K | 10.83M | 205.00K | 57.00K |
| Total Liabilities | 34.51M | 33.78M | 5.31M | 16.89M | 3.65M | 14.61M |
| Stockholders Equity | 30.74M | 54.56M | 23.07M | 12.72M | 31.97M | 38.70M |
Cash Flow | ||||||
| Free Cash Flow | -44.28M | -37.83M | -30.00M | -31.81M | -37.71M | -15.06M |
| Operating Cash Flow | -43.80M | -37.83M | -29.15M | -31.81M | -37.65M | -15.06M |
| Investing Cash Flow | -30.37M | -30.61M | -987.00K | -37.00K | -117.00K | 0 |
| Financing Cash Flow | 74.76M | 99.33M | 27.08M | 27.50M | 17.02M | 51.18M |
FluoGuide A/S Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:FLUO, the sentiment is Negative. The current price of 28.90 is below the 20-day moving average (MA) of 30.41, below the 50-day MA of 32.58, and below the 200-day MA of 36.25, indicating a bearish trend. The MACD of -0.82 indicates Positive momentum. The RSI at 37.78 is Neutral, neither overbought nor oversold. The STOCH value of 14.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:FLUO.
FluoGuide A/S Peers Comparison
Overall Rating
SE:FLUI58Neutral
SE:ONCO46Neutral
SE:BINV43Neutral
SE:SPAGO43Neutral
SE:BIOVIC.B41Neutral
SE:FLUO41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 58Neutral | SEK 37.78M | 13.99 | 21.37% | ― | 837.37% | ― | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 46Neutral | SEK 772.99M | -2.79 | ― | ― | 65.37% | 43.28% | |
| 43Neutral | SEK 201.36M | -0.41 | -128.54% | ― | -83.67% | -50.29% | |
| 43Neutral | SEK 34.97M | -1.17 | -87.37% | ― | -97.52% | 31.31% | |
| 41Neutral | SEK 89.52M | -1.30 | -75.51% | ― | 56.06% | 63.95% | |
| 41Neutral | SEK 480.67M | -6.51 | ― | ― | ― | -23.57% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:FLUO | FluoGuide A/S | 28.90 | -14.80 | -33.87% | |
| SE:BINV | BioInvent International AB | 3.02 | -28.18 | -90.32% | |
| SE:ONCO | Oncopeptides AB | 1.76 | -3.45 | -66.21% | |
| SE:BIOVIC.B | Biovica International AB Class B | 0.32 | -0.25 | -43.36% | |
| SE:SPAGO | Spago Nanomedical AB | 0.05 | -0.07 | -59.29% | |
| SE:FLUI | Fluicell AB | 28.60 | 15.30 | 115.04% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 27, 2026
